On 12th November 2018, the United States Food and Drugs Administration (US FDA) has provided the final approval to the Cipla Limited’s Valganciclovir 450mg Tablets, the generic version of Roche Valcyte.
Valganciclovir Tablets is an antiviral drug which is prescribed for the treatment of CMV (Cytomegalovirus) infection of the eye in adults with AIDS and also for the prevention of Cytomegalovirus (CMV) Infection which normally occurs after an organ transplant.
Cytomegalovirus Infection is normally caused when an organ transplant is done for organs like kidney, liver, pancreas and heart where the chances of infection are higher.
Valganciclovir450 tablets will prevent the replication of the virus and lower the symptoms of infection.
However, Valganciclovir is an alternate to Ganciclovir.
Cytomegalovirus retinitis (CMV) is a preventable late-stage infection in people suffering from HIV/AIDS mostly in low- and middle-income countries.
Accessibility and use of Valganciclovir for CMV in low and middle-income countries are currently very low.
The generic availability with the lowest affordable price is the only hope for those countries.
• Kindly consult your doctor before usage of Cipla’s Valganciclovir 450mg tablets.
• Like all medicines, this medicine can cause some side effects
Cipla is a well-known Indian pharmaceutical company which operates globally. It primarily focuses on generic medicines for oncology, hepatitis, respiratory, anti-retroviral, urology, cardiology and CNS segments.
If you have any questions, contact me. I am here to help you. You can contact me on WhatsApp +918851226314 or send me an email firstname.lastname@example.org